Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Baker Bros. Advisors and Acadia Pharmaceuticals Inc (NASDAQ:ACAD)

Baker Bros. Advisors purchased about 1.2 million shares of Acadia Pharmaceuticals Inc (NASDAQ:ACAD) for about $19 per share last week. Here is why the stock jumped from $14 to $20 in the last few days. Julian and Felix Baker’s multi-billion dollar hedge fund already owned more than 20% of the stock’s outstanding shares and the good news prompted them to add to their positions. You can get free email alerts by signing up below:

Julian Baker And Felix Baker
Julian Baker And Felix Baker
Baker Bros. Advisors

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Baker Bros. Advisors 28,570,614 0 28,570,614 0 28,570,614 22.8%
Baker Bros. Advisors (GP) 28,570,614 0 28,570,614 0 28,570,614 22.8%
Felix J. Baker 28,570,614 0 28,570,614 0 28,570,614 22.8%
Julian C. Baker 28,570,614 0 28,570,614 0 28,570,614 22.8%
Julian Baker And Felix Baker
Julian Baker And Felix Baker
Baker Bros. Advisors

Page 1 of 10 – SEC Filing

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13D

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT

TO RULE 13d-l(a) AND AMENDMENTS THERETO
FILED PURSUANT

TO RULE 13d-2(a)

(Amendment No. 12)*

ACADIA
Pharmaceuticals Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of
Securities)

004225108
(CUSIP number)

Alexandra A. Toohey

Chief Financial Officer

Baker Bros. Advisors LP

860 Washington Street, 3rd Floor

New York, NY 10014

(212) 339-5690

(Name,
address and telephone number of person authorized to receive notices and communications)

September 20, 2018
(Date of event which requires filing of this statement)

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.

(Continued on the following pages)

(Page 1 of 10 Pages)

________________________________

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
Trade (NASDAQ:ACAD) Now!
Loading...